![]() |
市場調查報告書
商品編碼
1700172
2032 年防打鼾設備市場預測:按產品類型、分銷管道、最終用戶和地區進行的全球分析Anti-Snoring Devices Market Forecasts to 2032 - Global Analysis By Product Type, Distribution Channel, End User and By Geography |
根據 Stratistics MRC 的數據,全球防打鼾設備市場預計在 2025 年將達到 10 億美元,到 2032 年將達到 21 億美元,預測期內的複合年成長率為 11.8%。
防打鼾裝置是醫療和消費產品,旨在透過改善睡眠時的氣流來減少或消除打鼾。這些設備透過解決打鼾的根本原因(例如氣道阻塞、舌頭位置不佳和喉嚨肌肉鬆弛)來發揮作用。常見的包括下顎前移裝置 (MAD)、舌固定裝置(TRD)、鼻擴張器和持續性呼吸道正壓通氣 (CPAP)。當氣道部分阻塞並且喉嚨中的軟組織振動時就會發生打鼾。
根據美國睡眠協會統計,大約有 5,000 萬至 7,000 萬美國成年人患有睡眠障礙,其中 48% 的人報告打鼾。據估計,在美國, 40% 的女性和 57% 的男性受到打鼾的影響。
睡眠障礙增多
阻塞型睡眠呼吸中止症呼吸中止症和慢性打鼾等睡眠障礙影響著數百萬人,導致健康併發症和生活品質下降。人們對這些疾病及其長期影響的認知不斷提高,促進了防打鼾裝置的普及。持續努力提高人們對睡眠健康重要性的認知,加上睡眠障礙診斷方面的進步,預計將成為市場成長的主要驅動力。
患者依從性低
許多患者因不適、不便以及對結果不滿意而停止使用這些設備。此外,缺乏對這些設備的正確使用和長期益處的認知也使問題變得更加複雜。不願意採用此類解決方案,尤其是在某些人口和地區,限制了它們的市場滲透。這些挑戰凸顯了改善設備設計和教育使用者以確保持續使用和合規的重要性。
技術進步和智慧防打鼾解決方案
連網防打鼾設備等產品與行動應用程式整合,可以監控睡眠模式並提供回饋,越來越受歡迎。這些先進的解決方案提供了更大的便利性、有效性和客製化性,以滿足消費者不斷變化的需求。隨著技術不斷縮小使用者體驗與臨床效果之間的差距,智慧設備的採用預計將推動市場顯著成長。
與手術衝突
懸壅垂顎咽整形術(UPPP) 和其他微創手術等選擇提供了永久性的解決方案,並可能限制對裝置的長期需求。儘管手術成本較高且有相關風險,但人們認為手術介入更有效,這對設備製造商構成了重大挑戰。這種競爭態勢要求不斷創新,以將防打鼾裝置定位為可靠的非侵入性替代品。
疫情擾亂了醫療保健服務,包括睡眠障礙的診斷和管理,導致防打鼾設備市場暫時放緩。封鎖和限制推遲了睡眠測試和麵對面諮詢,影響了設備的普及。然而,這段時期也見證了遠端醫療和虛擬訪問的興起,為診斷和治療開闢了新的途徑,並提高了人們對睡眠健康的認知。疫情過後,對遠距醫療解決方案的重視預計將增強市場的彈性和成長軌跡。
預計在預測期內,下顎突出矯正裝置部分將佔據最大的佔有率。
預計在預測期內,下顎突發設備部分將佔據最大的市場佔有率。下顎前移裝置透過重新定位下顎來保持呼吸道暢通,對治療輕度至中度睡眠呼吸中止症和打鼾非常有效。它的廣泛採用歸因於其易於使用、非侵入性以及經過驗證的臨床效果。隨著患者和醫療保健提供者對 MAD 認知的提高,其對市場收益的貢獻也預計將成長。
預計在預測期內,睡眠治療診所部分將以最高的複合年成長率成長。
由於人們對睡眠障礙的認知不斷提高,預計睡眠治療診所部門將在預測期內見證最高的成長率。睡眠治療診所為睡眠障礙患者提供診斷測試、個人化設備配件和後續護理等專業服務。他們能夠提供全面、客製化的解決方案,從而增加了需求,尤其是尋求專業指導的個人。預計睡眠治療基礎設施投資的增加和睡眠障礙盛行率的上升將推動該領域的快速擴張。
由於醫療保健支出的增加和中階的蓬勃發展,預計亞太地區將在預測期內佔據最大的市場佔有率。中國和印度等患者人數眾多且醫療設備取得管道便利的國家正成為主要市場。此外,政府促進睡眠健康的措施也推動了該地區防打鼾設備的採用。
預計北美地區在預測期內將呈現最高的複合年成長率。這主要歸功於該地區先進的醫療保健基礎設施、睡眠障礙的高發性以及強大的消費者意識。此外,持續的技術進步和主要市場參與者的存在正在推動創新和採用。有利的報銷政策和對非侵入性治療方案日益成長的偏好預計將進一步推動該地區的市場成長。
According to Stratistics MRC, the Global Anti-Snoring Devices Market is accounted for $1.0 billion in 2025 and is expected to reach $2.1 billion by 2032 growing at a CAGR of 11.8% during the forecast period. Anti-snoring devices are medical and consumer products designed to reduce or eliminate snoring by improving airflow during sleep. These devices work by addressing the underlying causes of snoring, such as airway obstruction, poor tongue positioning, or relaxed throat muscles. Common types include mandibular advancement devices (MADs), tongue-retaining devices (TRDs), nasal dilators, and continuous positive airway pressure (CPAP) machines. Snoring occurs when the airway is partially blocked, leading to vibrations in the soft tissues of the throat.
According to the American Sleep Association, approximately 50-70 million US adults have a sleep disorder and out of those, 48% report snoring. Snoring is estimated to affect 40% of women and 57% of men in the US.
Rising prevalence of sleep disorders
Sleep disorders such as obstructive sleep apnea and chronic snoring affect millions, leading to health complications and decreased quality of life. Increased awareness about these conditions and their potential long-term effects has further fueled the adoption of anti-snoring devices. Ongoing efforts to educate the public about the importance of sleep health, coupled with advances in diagnosing sleep disorders, are expected to be a key driver of market growth.
Low patient compliance
Many individuals discontinue the use of these devices due to discomfort, inconvenience, or dissatisfaction with the results. Additionally, inadequate awareness about the proper usage and long-term benefits of these devices exacerbates the problem. Resistance to adopting such solutions, especially in certain demographic groups or regions, limits market penetration. These challenges underscore the importance of improving device design and educating users to ensure sustained usage and compliance.
Technological advancements and smart anti-snoring solutions
Products such as connected anti-snoring devices, which integrate with mobile apps to monitor sleep patterns and provide feedback, are gaining traction. These advanced solutions offer enhanced convenience, effectiveness, and customization, catering to the evolving needs of consumers. As technology continues to bridge the gap between user experience and clinical efficacy, the adoption of smart devices is expected to drive significant growth in the market.
Competition from Surgery
Options such as uvulopalatopharyngoplasty (UPPP) and other minimally invasive surgeries offer permanent solutions, potentially limiting the long-term demand for devices. The perception of surgical interventions as more effective, despite their higher costs and associated risks, poses a significant challenge to device manufacturers. This competitive dynamic necessitates continuous innovation to position anti-snoring devices as a reliable, non-invasive alternative.
The pandemic disrupted healthcare services, including the diagnosis and management of sleep disorders, leading to a temporary slowdown in the anti-snoring devices market. Lockdowns and restrictions delayed sleep studies and in-person consultations, impacting device adoption rates. However, the rise of telemedicine and virtual consultations during this period offered new avenues for diagnosis and treatment, promoting awareness about sleep health. Post-pandemic, the emphasis on remote healthcare solutions is expected to strengthen the market's resilience and growth trajectory.
The mandibular advancement devices segment is expected to be the largest during the forecast period
The mandibular advancement devices segment is expected to account for the largest market share during the forecast period. Mandibular advancement devices are highly effective in treating mild to moderate cases of sleep apnea and snoring by repositioning the lower jaw to maintain an open airway. Their wide adoption can be attributed to their ease of use, non-invasive nature, and proven clinical efficacy. As awareness of MADs increases among patients and healthcare providers, their contribution to the market's revenue is expected to remain substantial.
The sleep therapy clinics segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the sleep therapy clinics segment is predicted to witness the highest growth rate due to growing awareness of sleep disorders. Sleep therapy clinics provide specialized services, including diagnostic tests, personalized device fittings, and follow-up care for sleep disorder patients. Their ability to offer comprehensive and tailored solutions has driven demand, especially among individuals seeking professional guidance. Growing investments in sleep therapy infrastructure and the rising prevalence of sleep disorders are expected to propel the segment's rapid expansion.
During the forecast period, the Asia Pacific region is expected to hold the largest market share attributed to increasing healthcare expenditure, and a burgeoning middle-class population contribute to this trend. Countries like China and India, with their large patient base and improving access to medical devices, are emerging as key markets. Additionally, government initiatives to promote sleep health are fostering the adoption of anti-snoring devices in the region.
Over the forecast period, the North America region is anticipated to exhibit the highest CAGR owing to the region's advanced healthcare infrastructure, high prevalence of sleep disorders, and strong consumer awareness are key contributors. Additionally, continuous technological advancements and the presence of leading market players drive innovation and adoption. Favorable reimbursement policies and increasing preference for non-invasive treatment options are further expected to bolster the market's growth in this region.
Key players in the market
Some of the key players in Anti-Snoring Devices Market include Vyaire Medical, Vivos Therapeutics Inc, Apple, The Pure Sleep Company, SomnoMed, Prosomnus Sleep Technologies, ResMed, Mitsui Chemicals, Meditas, Lumenis, Lear Corporation,Koninklijke Philips N.V, Innovative Health Technologies, Illusion Aligners, GSK Plc, Fisher & Paykel Healthcare Limited, ASF Medical GmbH, Apnea Sciences and AccuMED
In September 2024, Apple introduced a sleep apnea detection feature for its smartwatches, utilizing accelerometer data and machine learning to identify respiratory interruptions during sleep. This innovation aims to increase awareness and encourage medical consultations for sleep disorders.
In January 2023, Vivos Therapeutics Inc. received FDA clearance for its DNA appliance, designed to treat mild-to-moderate obstructive sleep apnea (OSA) and snoring. This device represents a significant advancement in non-invasive treatment options for sleep-related breathing disorders.